NasdaqCM - Nasdaq Real Time Price USD

Catalyst Pharmaceuticals, Inc. (CPRX)

14.89

+0.21

(+1.43%)

At close: April 26 at 4:00 PM EDT

15.19

+0.30

(+2.01%)

After hours: April 26 at 7:24 PM EDT

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2024 financial results after the market close

GlobeNewswire 4 days ago

CPRX
+1.43%
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company

Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be...

Simply Wall St. 8 days ago

CPRX
+1.43%
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024

In this article, we will take a detailed look at Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024. For a quick overview of such stocks, read our article Jim Cramer’s 5 Favorite Healthcare Stock Picks in 2024. Jim Cramer kicked off 2024 with a positive note for the healthcare sector, saying in a program in January that the […]

Insider Monkey 13 days ago

OMI

ITGR

ADUS
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 28 days ago

CPRX
+1.43%
CORT
+2.66%
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th

GlobeNewswire 29 days ago

CPRX
+1.43%
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtual

GlobeNewswire 30 days ago

CPRX
+1.43%
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy biotech stocks are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. Given the timeline of clinical trials and new rele

InvestorPlace 30 days ago

AXSM
+0.27%
KRYS

CPRX
+1.43%
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...

Simply Wall St. last month

CPRX
+1.43%
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

CRNX

CPRX
+1.43%
7 Biotech Stocks Ready to Ride the Sector’s Resurgence

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r

InvestorPlace last month

TECH

CNTA

CPRX
+1.43%
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for Patients Aged Two Years and Older Catalyst Pathways® Program will Support AGAMREE Patients and Available to Help Ensure DMD Patients Affordable Access and Product Education CORAL GABLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage

GlobeNewswire last month

CPRX
+1.43%
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio

If you want big returns, you gotta think small – as in small-cap stocks. That’s not to say the large-capitalization enterprises can’t get you to investment Valhalla. However, the most diminutive companies have math on their side. Basically, I’m referring to the law of small numbers. When you’re dealing with small-cap stocks, you’re almost always targeting businesses that don’t generate much attention. So, when a less-appreciated firm presents impressive financial performance metrics, they can se

InvestorPlace last month

ACMR

CPRX
+1.43%
ATEC
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conferen

GlobeNewswire last month

CPRX
+1.43%
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CPRX
+1.43%
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million, $1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 202

GlobeNewswire last month

CPRX
+1.43%
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD)

GlobeNewswire last month

CPRX
+1.43%
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of VamoroloneCORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for p

GlobeNewswire 2 months ago

CPRX
+1.43%
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ETCORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2023 financial results after the market c

GlobeNewswire 2 months ago

CPRX
+1.43%
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 3 months ago

CPRX
+1.43%
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022. This suggests a positive outlook for the U.S. economy in the coming months. With our economy, looking to perform well this year you need to invest in these biotech stocks that will provide high retu

InvestorPlace 3 months ago

VNRX

CPRX
+1.43%

Performance Overview

Return	CPRX	S&P 500
YTD	-11.42%	+6.92%
1-Year	-7.46%	+25.26%
3-Year	+218.84%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company

Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

7 Biotech Stocks Ready to Ride the Sector’s Resurgence

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

Performance Overview